Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes mellitus (T2DM)~* On stable diabetes therapy of metformin with either sitagliptin or another dipeptidyl peptidase-4 (DPP-4) inhibitor or a sulfonylurea (SU) prior to study participation and is willing to wash-off/switch from another DPP-4 inhibitor/SU to sitagliptin~* Body Mass Index (BMI) greater than or equal to 18.0 kg/m\^2~* Male, postmenopausal female or surgically sterile female~* If a female of reproductive potential, agrees to remain abstinent or to use (or have their partner use) 2 acceptable combinations of birth control while participating in the trial and for 14 days after the last use of study drug~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrine disorders, drug- or chemical-induced, and post-organ transplant)~* A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) or DPP-4 inhibitor~* On a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable~* Has undergone bariatric surgery within the past 12 months or \>12 months and is not weight stable~* Has been treated with insulin (except for short-term use \[\<= 7 days\]), injectable antihyperglycemic agents (AHAs) (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other sodium-glucose co-transporter 2 (SGLT2) inhibitors, alpha glucosidase inhibitors or meglitinides, bromocriptine (Cycloset™), colesevelam (Welchol™), or any other non-protocol approved AHAs within 12 weeks of study participation~* Has active, obstructive uropathy or indwelling urinary catheter~* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation~* A history of malignancy ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer~* Known history of Human Immunodeficiency Virus (HIV)~* Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells or any other clinically significant hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)~* A medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or active symptomatic gallbladder disease~* Has any clinically significant malabsorption condition~* If taking thyroid replacement therapy, has not been on a stable dose for at least 6 weeks prior to study participation~* Has been previously randomized in a study with ertugliflozin~* Has participated in other studies involving an investigational drug within 30 days prior or during study participation~* Has undergone a surgical procedure within 6 weeks prior to or planned major surgery during study participation~* Has a positive urine pregnancy test~* Is pregnant or breast-feeding, or is planning to conceive during the trial, including 14 days following the last dose of study medication~* Planning to undergo hormonal therapy in preparation to donate eggs during the trial, including 14 days following the last dose of study medication~* Excessive consumption of alcoholic beverages or binge drinking~* Has donated blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin 5 mg (Type: EXPERIMENTAL): Ertugliflozin, 5 mg, oral, once daily for 52 weeks
- Ertugliflozin 15 mg (Type: EXPERIMENTAL): Ertugliflozin, 15 mg, oral, once daily for 52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to ertuglifozin, oral, once daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).